Luis E. Santos, Paulo Mattos, Thais L. Pinheiro, Ananssa Silva, Claudia Drummond, Felipe Kenji Sudo, Fernanda Barros-Aragão, Bart Vanderborght, Carlos Otávio Brandão, Sergio T. Ferreira, Fernanda Tovar-Moll, Fernanda G. De Felice
{"title":"Performance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort","authors":"Luis E. Santos, Paulo Mattos, Thais L. Pinheiro, Ananssa Silva, Claudia Drummond, Felipe Kenji Sudo, Fernanda Barros-Aragão, Bart Vanderborght, Carlos Otávio Brandão, Sergio T. Ferreira, Fernanda Tovar-Moll, Fernanda G. De Felice","doi":"10.1038/s41467-025-56756-3","DOIUrl":null,"url":null,"abstract":"<p>Despite remarkable progress in the biomarker field in recent years, local validation of plasma biomarkers of Alzheimer’s disease (AD) and dementia is still lacking in Latin America. In this longitudinal cohort study of 145 elderly Brazilians, we assess the diagnostic performance of plasma biomarkers, based on clinical diagnosis and CSF biomarker positivity. Follow-up data of up to 4.7 years were used to determine performance in predicting diagnostic conversions. Participants were clinically categorized as cognitively unimpaired (<i>n</i> = 49), amnestic mild cognitive impairment (<i>n</i> = 29), AD (<i>n</i> = 38), Lewy body dementia (<i>n</i> = 22), or vascular dementia (<i>n</i> = 7). Plasma Tau, Aβ<sub>40</sub>, Aβ<sub>42</sub>, NfL, GFAP, pTau231, pTau181 and pTau217 were measured on the SIMOA HD-X platform. Plasma pTau217 showed excellent performance determining CSF biomarker status in the cohort, either alone (ROC AUC = 0.94, 95% CI: [0.88–1.00]) or as a ratio to Aβ<sub>42</sub> (ROC AUC = 0.98, 95% CI: [0.94–1.00]). This study comprises an initial step towards local validation and adoption of dementia biomarkers in Brazil.</p>","PeriodicalId":19066,"journal":{"name":"Nature Communications","volume":"41 1","pages":""},"PeriodicalIF":14.7000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Communications","FirstCategoryId":"103","ListUrlMain":"https://doi.org/10.1038/s41467-025-56756-3","RegionNum":1,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
Performance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort
Despite remarkable progress in the biomarker field in recent years, local validation of plasma biomarkers of Alzheimer’s disease (AD) and dementia is still lacking in Latin America. In this longitudinal cohort study of 145 elderly Brazilians, we assess the diagnostic performance of plasma biomarkers, based on clinical diagnosis and CSF biomarker positivity. Follow-up data of up to 4.7 years were used to determine performance in predicting diagnostic conversions. Participants were clinically categorized as cognitively unimpaired (n = 49), amnestic mild cognitive impairment (n = 29), AD (n = 38), Lewy body dementia (n = 22), or vascular dementia (n = 7). Plasma Tau, Aβ40, Aβ42, NfL, GFAP, pTau231, pTau181 and pTau217 were measured on the SIMOA HD-X platform. Plasma pTau217 showed excellent performance determining CSF biomarker status in the cohort, either alone (ROC AUC = 0.94, 95% CI: [0.88–1.00]) or as a ratio to Aβ42 (ROC AUC = 0.98, 95% CI: [0.94–1.00]). This study comprises an initial step towards local validation and adoption of dementia biomarkers in Brazil.
期刊介绍：
Nature Communications, an open-access journal, publishes high-quality research spanning all areas of the natural sciences. Papers featured in the journal showcase significant advances relevant to specialists in each respective field. With a 2-year impact factor of 16.6 (2022) and a median time of 8 days from submission to the first editorial decision, Nature Communications is committed to rapid dissemination of research findings. As a multidisciplinary journal, it welcomes contributions from biological, health, physical, chemical, Earth, social, mathematical, applied, and engineering sciences, aiming to highlight important breakthroughs within each domain.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
